Track topics on Twitter Track topics that are important to you
Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...
Baxter is one of the 30 largest pharmaceutical companies in the world with annual sales of $7.8 billion. With a foot in both the pharmaceutical industry and medical devices, Baxter Healthcare has ...
Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...
Piramal Enterprises inked an agreement to acquire Ash Stevens, a U.S. based contract development and manufacturing organization for $42.95 million plus an earn-out consideration capped at $10 millio...
Ash Stevens has announced that it has been acquired by Piramal Pharma Solutions, an India-based CDMO, in a deal worth $42.95m
Ash Stevens has been acquired by Piramal Pharma Solutions, an India-based CDMO, in what the CEO said is an "incredibly powerful combination."
US-based Ash Stevens will add high potency capabilities to the services that the Indian firm offers. The post Piramal to Acquire CDMO Ash Stevens for US$53M appeared first on PharmaAsia.
Hoboken, NJ (PRWEB) May 11, 2016 Stevens Institute of Technology has announced the launch of a new $150 million, three-year campaign...
The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.
(PRWEB) June 14, 2016 Fire Door Solutions, headquartered in Overland Park, Kansas, in response to CMSâ adoption of the 2012 Lif...
NewsPiramal Enterprises enters into an agreement to acquire Ash Stevens Inc., a US based CDMO for high potency APIs (HPAPIs).
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) corresponds to a rare and acute life-threatening mucocutaneous reactions characterized by extensive necrosis and epidermal detachmen...
Recent advances and outcomes data in the management of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) demonstrate the need for a universal standard of care for patients admitted wit...
Effective pre-clinical research is a vital component in the development of MRI-guided focused ultrasound (MRgFUS) and its translation to clinic. In this review we seek to outline the challenges at han...
Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening and severe adverse cutaneous drug reactions characterized by epidermal detachment presenting as blisters and ar...